Accelr8 Technology Corporation
(NYSE Amex: AXK) announced that the company received notice of an ICAAC Program Committee Award in the area of Clinical Microbiology and Diagnosis. The award recognizes the “outstanding presentation of an abstract accepted by ICAAC” for the 51
ICAAC to be held in Chicago on September 17-20, 2011. The award will be presented at the meeting. The presentation title is “Same-Shift ID Directly from Respiratory Specimens by Automated Microscopy.” It will report results from a study using Accelr8’s BACcel™ rapid diagnostic system in collaboration with investigators at the Barnes-Jewish Hospital in St. Louis.
Accelr8 will announce the study results at the time of the presentation.
) is the annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Organized by the American Society for Microbiology (
), ICAAC is a major global congress for Clinical Microbiology and Infectious Diseases Medicine.
In additional news, Accelr8 received notice of issuance for a Japanese patent on the BACcel™ system. The new patent joins previously issued US and international patents to broaden Accelr8’s global patent coverage for the BACcel™ system.
According to David Howson, Accelr8’s president, “We are honored by the recognition from ICAAC’s review committee. It reflects the BACcel™ system’s potential importance in Clinical Microbiology. Our culture-free methods have repeatedly demonstrated the unprecedented ability to quantitatively identify multiple pathogens directly from patient specimens in less than 2 hours. Our pilot clinical studies pass the ‘real specimen’ hurdle that continues to stymie new attempts to replace multi-day culturing. The BACcel™ system continues to widen its lead in helping to fight the worsening global antibiotic resistance pandemic.”
Accelr8 Technology Corporation (
) is a developer of innovative materials and instrumentation for advanced applications in medical instrumentation, basic research, drug discovery, and bio-detection. Accelr8 is developing a rapid analytical platform for infectious pathogens, the BACcel™ system, based on its innovative surface coatings, assay processing, and detection technologies. In addition, Accelr8 licenses certain of its proprietary technology for use in applications outside of Accelr8’s own products.
Certain statements in this news release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding future prospects and developments are based upon current expectations and involve certain risks and uncertainties that could cause actual results and developments to differ materially from the forward-looking statement, including those detailed in the company's filings with the Securities and Exchange Commission. Accelr8 does not undertake an obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events.